HOLX News and Press, Hologic Inc. From 10/06/20

The FDA has broadened its emergency use authorization ((EUA)) of Hologic's (HOLX) Aptima SARS-CoV-2 assay to include testing of people without symptoms or other reasons to suspect COVID-19 infection.Last week, the agency OK'd similar claims for the company's Panther Fusion SARS-CoV-2 test. ...

Hologic, Inc. (Nasdaq: HOLX) announced today that its Aptima® SARS-CoV-2 assay, which initially received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) in May, is now authorized for testing of individuals without symptoms or other reasons to susp...

Initiative includes awareness campaign featuring Mary J. Blige and funding for screening and diagnostic services at approximately 15 U.S. facilities Hologic, Inc. (Nasdaq: HOLX), an innovative medical technology company primarily focused on improving women’s health, t...

Hologic (HOLX) announces emergency use authorization in the U.S. for its Panther Fusion SARS-CoV-2 molecular assay for use in testing asymptomatic people for COVID-19 infection (in other words, the high-throughput test can be used to screen people who may have been exposed to an infected pers...

- Testing of Pooled Samples Also Authorized; New Claims Expected to Help Limit Spread of COVID-19, Open Economy and Schools - Hologic, Inc. (Nasdaq: HOLX) announced today that its Panther Fusion® SARS-CoV-2 assay has received Emergency Use Authorization (EUA) from the U...

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week aheadA relatively light earnings and conference calendar in the week ahead doesn't mean a break for investors. The U.S. airlin...

Shortages of reagents, essential chemicals used in diagnostic assays, are the latest supply issue hampering U.S. health systems in their efforts to offer COVID-19 tests to all who need or request them. Some hospitals and other testing operations have returned to restricting tests to the most ...

Hologic (NASDAQ: HOLX ) has priced its $950M of 3.250% senior notes due 2029 at an issue price of $1,000 per $1,000. More news on: Hologic, Inc., Healthcare stocks news, , Read more ...

Hologic, Inc. (Nasdaq: HOLX) announced today that it has priced its previously announced private offering of $950 million aggregate principal amount of 3.250% senior notes due 2029 at an issue price of $1,000 per $1,000. The 2029 notes will be unsecured obligations of the Company and will be ...

-- Proceeds from Offering Will Be Used to Refinance Existing 4.375% Senior Unsecured Notes Due 2025 -- Hologic, Inc. (Nasdaq: HOLX) announced today that it has launched, subject to market and other conditions, a private offering of $950 million aggregate principal amount of senior notes ...